Barclays PLC Boosts Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Barclays PLC increased its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 357.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,837 shares of the medical instruments supplier's stock after purchasing an additional 6,905 shares during the quarter. Barclays PLC owned 0.16% of Mesa Laboratories worth $1,148,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of MLAB. Canada Pension Plan Investment Board purchased a new stake in shares of Mesa Laboratories during the second quarter worth approximately $26,000. FMR LLC increased its position in shares of Mesa Laboratories by 34.1% in the 3rd quarter. FMR LLC now owns 393 shares of the medical instruments supplier's stock valued at $51,000 after purchasing an additional 100 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Mesa Laboratories during the 3rd quarter worth $70,000. Sanctuary Advisors LLC acquired a new position in shares of Mesa Laboratories during the second quarter worth $183,000. Finally, Berry Wealth Group LP purchased a new position in Mesa Laboratories in the third quarter valued at $204,000. Hedge funds and other institutional investors own 90.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MLAB. StockNews.com cut Mesa Laboratories from a "buy" rating to a "hold" rating in a research report on Wednesday, November 13th. Evercore ISI upped their price target on Mesa Laboratories from $120.00 to $160.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st.

Insider Buying and Selling

In other Mesa Laboratories news, CEO Gary M. Owens sold 2,518 shares of the firm's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $113.62, for a total transaction of $286,095.16. Following the transaction, the chief executive officer now directly owns 45,888 shares of the company's stock, valued at approximately $5,213,794.56. This trade represents a 5.20 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 4.40% of the stock is currently owned by company insiders.

Mesa Laboratories Stock Performance

MLAB traded down $1.02 on Monday, reaching $132.04. The company had a trading volume of 22,211 shares, compared to its average volume of 41,441. The stock has a 50-day moving average price of $120.56 and a 200-day moving average price of $117.45. The stock has a market capitalization of $717.11 million, a PE ratio of -2.90 and a beta of 0.86. Mesa Laboratories, Inc. has a 1 year low of $83.68 and a 1 year high of $141.17. The company has a quick ratio of 0.51, a current ratio of 0.70 and a debt-to-equity ratio of 0.65.

Mesa Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Friday, November 29th were given a $0.16 dividend. The ex-dividend date was Friday, November 29th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.48%. Mesa Laboratories's dividend payout ratio (DPR) is presently -1.40%.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.